Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Supplemental Table S1. DNA oligos used in this study Supplemental Table S2. Characteristics of patients with primary melanomas and cutaneous melanoma metastasis (Bonn cohorts). Supplemental Table S4. List of transcription factors binding in NT5E based on ENCODE ChIP-seq data. Supplemental Table S8. Changes of CD73 IHC score in melanoma patients from the UCLA cohort under pembrolizumab treatment (anti-PD-1). Supplemental Table S9. Characteristics and changes of CD73 expressions of melanomas from patients of the Sydney cohort treated with nivolumab or pembrolizumab (anti PD-1).